ACM Global Central Lab has advanced its hybrid central lab model in Mumbai with a state-of-the art operational facility dedicated to manage clinical trials testing in India and provide study support throughout Asia Pacific. Working in conjunction with the largest diagnostic lab in the region, ACM Global oversees the full complement of study support to keep clinical trials on schedule and on budget, including kit building, shipping logistics, projectmanagement, data management, and site support.
“We have been able to build a local team that thoroughly understands the nuances of the market, plus the systems and process at ACM Global to maintain our high global standard for global clinical trial testing,” said Nandan Rao, director, India and general manager, Asia Pacific at ACM Global Central Lab.
ACM Global first established an operational footprint in India seven years ago, and established its hybrid lab model three years ago to support increased activity in the Asia Pacific region. This has enabled ACM Global to take advantage of an established, regional central lab while benefitting from its own advanced data management systems for the centralization and harmonization of test data. With a local staff, data is integrated immediately with the centralized database, and shipping and logistics are navigated at the local level, which means tighter specimen controls and lower total costs to the sponsor.
All studies conducted by the CAP-certified lab are assured precise analytical data managed from a central location with one harmonized database
.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.